Efficacy of bevacizumab and chemotherapy in the first-line
treatment of metastatic colorectal cancer: broadening
KRAS-focused clinical view

J 2015

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view

BENCSIKOVÁ, Beatrix, Zbyněk BORTLÍČEK, Jana HALÁMKOVÁ, Lenka OSTRIZKOVA, Igor KISS et. al.

Basic information

Original name

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view

Authors

BENCSIKOVÁ, Beatrix (703 Slovakia, guarantor), Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution), Jana HALÁMKOVÁ (203 Czech Republic), Lenka OSTRIZKOVA (203 Czech Republic), Igor KISS (203 Czech Republic), Bohuslav MELICHAR (203 Czech Republic), Tomáš PAVLÍK (203 Czech Republic, belonging to the institution), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Dalibor VALÍK (203 Czech Republic), Rostislav VYZULA (203 Czech Republic) and Lenka ZDRAŽILOVÁ DUBSKÁ (203 Czech Republic, belonging to the institution)

Edition

BMC Gastroenterology, LONDON, BioMed Central, 2015, 1471-230X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.101

RIV identification code

RIV/00216224:14110/15:00084399

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1186/s12876-015-0266-6

UT WoS

000351720700001

Keywords in English

Colorectal cancer; Angiogenesis inhibitors; Bevacizumab; KRAS; Biomarkers; Antineoplastic agents; Clinical practice

Abstract

V originále

Background: The aim of the present retrospective study was to analyze clinical outcome and risk factors associated with treatment outcomes according to KRAS status in patient with metastatic colorectal cancer (mCRC) treated with bevacizumab (bev) plus chemotherapy in the first-line setting. Methods: We performed observational study on 1622 patients with mCRC treated with bev plus oxaliplatin- or irinotecan-based chemotherapy, and correlated treatment outcomes with KRAS mutation status. The primary endpoint was progression-free survival (PFS) and additionally overall survival (OS). Adverse events of bevacizumab and risk factors including location of metastases were evaluated. Results: Mutation in KRAS was present in 40.6% of mCRC cases. The median PFS in patients with wild-type KRAS (wtKRAS) vs mutant KRAS was 11.5 vs 11.4 months, respectively. The median OS was 30.7 vs 28.4 months (p = 0.312). Patients with KRAS mutation had lung metastases more frequently than wtKRAS individuals (32.0% vs 23.8%; p = 0.001). We observed no difference in clinical outcome between hepatic and extrahepatic metastatic disease. Conclusion: KRAS mutation does not interfere with clinical benefit from first-line treatment with bevacizumab plus chemotherapy in mCRC patients.

Citovat

BENCSIKOVÁ, Beatrix, Zbyněk BORTLÍČEK, Jana HALÁMKOVÁ, Lenka OSTRIZKOVA, Igor KISS, Bohuslav MELICHAR, Tomáš PAVLÍK, Ladislav DUŠEK, Dalibor VALÍK, Rostislav VYZULA and Lenka ZDRAŽILOVÁ DUBSKÁ. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. BMC Gastroenterology. LONDON: BioMed Central, 2015, vol. 15, MAR 24 2015, p. "nestránkováno", 10 pp. ISSN 1471-230X. Available from: https://dx.doi.org/10.1186/s12876-015-0266-6.

@article{1315243,
   author = {Bencsiková, Beatrix and Bortlíček, Zbyněk and Halámková, Jana and Ostrizkova, Lenka and Kiss, Igor and Melichar, Bohuslav and Pavlík, Tomáš and Dušek, Ladislav and Valík, Dalibor and Vyzula, Rostislav and Zdražilová Dubská, Lenka},
   article_location = {LONDON},
   article_number = {MAR 24 2015},
   doi = {http://dx.doi.org/10.1186/s12876-015-0266-6},
   keywords = {Colorectal cancer; Angiogenesis inhibitors; Bevacizumab; KRAS; Biomarkers; Antineoplastic agents; Clinical practice},
   language = {eng},
   issn = {1471-230X},
   journal = {BMC Gastroenterology},
   title = {Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view},
   volume = {15},
   year = {2015}
}

TY  - JOUR
ID  - 1315243
AU  - Bencsiková, Beatrix - Bortlíček, Zbyněk - Halámková, Jana - Ostrizkova, Lenka - Kiss, Igor - Melichar, Bohuslav - Pavlík, Tomáš - Dušek, Ladislav - Valík, Dalibor - Vyzula, Rostislav - Zdražilová Dubská, Lenka
PY  - 2015
TI  - Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
JF  - BMC Gastroenterology
VL  - 15
IS  - MAR 24 2015
SP  - "nestránkováno"
EP  - "nestránkováno"
PB  - BioMed Central
SN  - 1471230X
KW  - Colorectal cancer
KW  - Angiogenesis inhibitors
KW  - Bevacizumab
KW  - KRAS
KW  - Biomarkers
KW  - Antineoplastic agents
KW  - Clinical practice
N2  - Background: The aim of the present retrospective study was to analyze clinical outcome and risk factors associated with treatment outcomes according to KRAS status in patient with metastatic colorectal cancer (mCRC) treated with bevacizumab (bev) plus chemotherapy in the first-line setting. Methods: We performed observational study on 1622 patients with mCRC treated with bev plus oxaliplatin- or irinotecan-based chemotherapy, and correlated treatment outcomes with KRAS mutation status. The primary endpoint was progression-free survival (PFS) and additionally overall survival (OS). Adverse events of bevacizumab and risk factors including location of metastases were evaluated. Results: Mutation in KRAS was present in 40.6% of mCRC cases. The median PFS in patients with wild-type KRAS (wtKRAS) vs mutant KRAS was 11.5 vs 11.4 months, respectively. The median OS was 30.7 vs 28.4 months (p = 0.312). Patients with KRAS mutation had lung metastases more frequently than wtKRAS individuals (32.0% vs 23.8%; p = 0.001). We observed no difference in clinical outcome between hepatic and extrahepatic metastatic disease. Conclusion: KRAS mutation does not interfere with clinical benefit from first-line treatment with bevacizumab plus chemotherapy in mCRC patients.
ER  -

BENCSIKOVÁ, Beatrix, Zbyněk BORTLÍČEK, Jana HALÁMKOVÁ, Lenka OSTRIZKOVA, Igor KISS, Bohuslav MELICHAR, Tomáš PAVLÍK, Ladislav DUŠEK, Dalibor VALÍK, Rostislav VYZULA and Lenka ZDRAŽILOVÁ DUBSKÁ. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. \textit{BMC Gastroenterology}. LONDON: BioMed Central, 2015, vol.~15, MAR 24 2015, p.~''nestránkováno'', 10 pp. ISSN~1471-230X. Available from: https://dx.doi.org/10.1186/s12876-015-0266-6.

Detailed Information on Publication Record